Aspiriant LLC Has $2.56 Million Stock Position in Abbott Laboratories (NYSE:ABT)

Aspiriant LLC decreased its stake in shares of Abbott Laboratories (NYSE:ABT) by 3.4% during the 1st quarter, Holdings Channel reports. The institutional investor owned 19,260 shares of the healthcare product maker’s stock after selling 674 shares during the period. Aspiriant LLC’s holdings in Abbott Laboratories were worth $2,555,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Tallon Kerry Patrick acquired a new position in Abbott Laboratories during the 4th quarter valued at about $200,000. LaFleur & Godfrey LLC lifted its position in Abbott Laboratories by 23.5% during the 4th quarter. LaFleur & Godfrey LLC now owns 82,443 shares of the healthcare product maker’s stock valued at $9,325,000 after purchasing an additional 15,692 shares during the period. Brighton Jones LLC lifted its position in Abbott Laboratories by 10.1% during the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after purchasing an additional 4,755 shares during the period. Union Bancaire Privee UBP SA acquired a new stake in shares of Abbott Laboratories in the 4th quarter valued at approximately $29,120,000. Finally, Van ECK Associates Corp raised its position in shares of Abbott Laboratories by 3.5% in the 4th quarter. Van ECK Associates Corp now owns 28,683 shares of the healthcare product maker’s stock valued at $3,244,000 after acquiring an additional 957 shares during the period. Institutional investors and hedge funds own 75.18% of the company’s stock.

Analysts Set New Price Targets

ABT has been the topic of a number of analyst reports. Piper Sandler reiterated an “overweight” rating and issued a $145.00 price target (up from $133.00) on shares of Abbott Laboratories in a research report on Thursday, April 17th. Citigroup increased their price target on shares of Abbott Laboratories from $135.00 to $160.00 and gave the company a “buy” rating in a research report on Tuesday, March 4th. Barclays increased their price target on shares of Abbott Laboratories from $158.00 to $159.00 and gave the company an “overweight” rating in a research report on Thursday, April 17th. The Goldman Sachs Group increased their target price on Abbott Laboratories from $138.00 to $154.00 and gave the stock a “buy” rating in a research note on Tuesday, March 4th. Finally, Leerink Partnrs raised Abbott Laboratories to a “hold” rating in a research note on Monday. Six equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Abbott Laboratories presently has an average rating of “Moderate Buy” and an average target price of $142.61.

Insider Activity

In related news, Director Sally E. Blount sold 2,600 shares of the business’s stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $129.66, for a total value of $337,116.00. Following the completion of the transaction, the director now owns 34,058 shares of the company’s stock, valued at $4,415,960.28. The trade was a 7.09% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.46% of the stock is currently owned by company insiders.

Abbott Laboratories Trading Down 1.4%

ABT stock opened at $132.18 on Wednesday. The company has a fifty day moving average price of $131.80 and a two-hundred day moving average price of $126.62. The stock has a market cap of $229.97 billion, a price-to-earnings ratio of 17.14, a price-to-earnings-growth ratio of 2.53 and a beta of 0.73. Abbott Laboratories has a one year low of $99.71 and a one year high of $141.23. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.78 and a quick ratio of 1.27.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.07 by $0.02. The company had revenue of $10.36 billion during the quarter, compared to analysts’ expectations of $10.38 billion. Abbott Laboratories had a net margin of 31.89% and a return on equity of 19.01%. Equities analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 15th. Stockholders of record on Tuesday, July 15th will be given a $0.59 dividend. The ex-dividend date of this dividend is Tuesday, July 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.79%. Abbott Laboratories’s payout ratio is presently 30.61%.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.